This is an international multicohort study of patients with HCC accrued from four continents who did not receive any anticancer treatment aimed to estimate the effect of HIV seropositivity on patients’ overall survival while accounting for common prognostic factors and demographic characteristics in uni- and multivariable models. A total of 1,588 patients were recruited, 132 of whom were HIV positive. Median OS of patients who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2 months [bootstrap 95% CI, 1.2 to 3.1 months] v 4.1 months [95% CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased the hazard of death by 24% ( P = .0333) independent of BCLC ( P < .0001), CTP ( P < .0001), α-fetoprotein ( P < .0001), geographical origin ( P < .0001), and male sex ( P = .0016).
(Pinato DJ et al. – Journal of Clinical Oncology, 18 December 2018)